SecBot SecBot

SEPN

Septerna, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001984086 Biotech & Drug Discovery
$41.67 −0.93 (−2.18%)
Nov 16 4:00 PM ET · prev $42.60
Market cap
$2.0B
Small cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$60.00
+44% · range $48.00–65.00
Next earnings
Nov 25
in 9 days · EPS est. −$0.29
1 year
+92.6%
from $21.64 · Nov 17
30 days
+14.5%
from $36.38
52-week range
$21.64–52.34
−20% from high · low Nov 17
Avg volume 20D
425.8K
Nov 11 spike 1.13M
Short interest
3.35M
≈7.2% of shares · −4.8%
Days to cover
11.9
at average volume
Insider net
−$45.8M
0 buyers · 6 sellers · since Jun 1
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 0 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 6/9 ·Next Earnings date, Nov 25, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $45.8M.

  • InstitutionsBULLISH

    Q2 2026: 17 added (1 new), 4 trimmed or exited. Largest new: Loomis Sayles & L P $20.9M.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.552 → −$0.397 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.8% to 3.35M shares. 11.9 days to cover, ≈7.2% of shares.

  • TrendUPTREND

    3% above its 50-day average. New closing high $52.34 on Nov 10.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$20.9M
in new stakes
FundMoveSharesValue
LOOMIS SAYLES & CO L PNEW624,752$20.9M
BALYASNY ASSET MANAGEMENT L.P.ADD350,442$11.7M
JACOBS LEVY EQUITY MANAGEMENT, INCDOUBLED68,180$2.3M
MILLENNIUM MANAGEMENT LLCTRIM50,562$1.7M
BARCLAYS PLCDOUBLED49,821$1.7M
Nuveen, LLCADD48,229$1.6M
Russell Investments Group, Ltd.DOUBLED40,209$1.3M
BANK OF AMERICA CORP /DE/ADD35,875$1.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy5Buy10Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +44%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Stifel
MAINTAIN
MAINTAINBuy
Nov 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 4, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Aug 19, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 13, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Aug 12, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$45.8M
sold · 6 insiders
DateInsiderTypeValue
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$319.2K
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$620.6K
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$1.1M
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$1.5M
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$207.3K
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$102.5K
Nov 11, 2026
Ezekowitz Alan
Director
Nov 11, 2026
SELL$54.8K
Oct 15, 2026
Bhatt Elizabeth
President and COO
Oct 15, 2026
EXERCISE$27.2K

Earnings setup

Estimates
Nov 25
reports in 9 days
−$0.29
EPS estimate, this quarter
+28%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.29-$0.69–-$0.24+4.0%$21.8M
Next Q-$0.39-$0.41–-$0.06-4.1%$15.7M
Current FY-$1.10-$1.35–-$0.74+7.4%$92.7M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,352,395
shares short
-4.8%
vs prior settlement
11.9
days to cover
≈7.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Samsara BioCapital, L.P., a significant shareholder in Septerna, filed a Form 144 notice of intent to sell 306,645…
144 · Impact 3/10
Nov 12, 2026 SEC
Director Jeffrey Finer filed a Form 144 notice of intent to sell 66,000 shares of Septerna common stock, with an…
144 · Impact 2/10
Nov 12, 2026 SEC
Director Alan Ezekowitz filed a Form 144 to sell 100,000 shares of Septerna, Inc. with an estimated aggregate value of…
144 · Impact 3/10
Nov 11, 2026 Insider
Ezekowitz Alan sold 6,939 shares
Director @ $46.01 ($319.2K)
Nov 11, 2026 Insider
Ezekowitz Alan sold 13,201 shares
Director @ $47.01 ($620.6K)
Nov 11, 2026 Insider
Ezekowitz Alan sold 22,865 shares
Director @ $47.78 ($1.1M)
Nov 9, 2026 Earnings
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027
Nov 4, 2026 Press
Septerna announced the selection of SEP-204, a potential first-in-class oral TSHR negative allosteric modulator, as a…
Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

19 filings · 4 press releases · 0 bullish · 6 bearish · 13 neutral
All SEPN filing & press-release reports (23)